Semprus BioSciences' mission is to establish a new standard-of-care by significantly reducing serious health complications associated with medical devices, improving patient outcomes and contributing to healthcare cost efficiencies.
Semprus BioSciences has a dual mission: to provide complication-free medical devices designed to preserve patients' long-term health and quality-of-life and to contribute to healthcare cost efficiencies. Our innovative, multi-faceted approach to durable surface modifications signifies a breakthrough in medical device technology. Our current focus is to reduce thrombus accumulation and platelet adhesion on vascular access catheters with a single surface modification.
Founded out of the Massachusetts Institute of Technology's Langer Lab, the company has developed the next-generation biofunctional surface platform - which is focused on achieving clinical benefits that far exceed current market offerings containing silver, heparin, and antibiotic coatings. Through covalent chemical bonding of our Semprus Sustain Technology, a permanent non-leaching biomaterial modification to the device surface, our technology is expected to vastly improve patient outcomes by preventing serious medical complications, such as infection, blood clots, improper healing, and cell overgrowth. We have assembled a world class product development team - scientists, industry executives and clinical experts - who specialize in reducing such complications at the confluence of the human body and implantable devices.
Additionally, we have worldwide licenses secured from MIT and the University of Washington, and hold numerous proprietary intellectual property filings. Our laboratory and office complex is located in Kendall Square, Cambridge's innovative biomedical center.
In May 2012, Semprus was acquired by Teleflex, Inc.